Page 83 - Read Online

Page 12 of 15 Osho et al. Hepatoma Res 2020;6:55 I http://dx.doi.org/10.20517/2394-5079.2020.42
5. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients
with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
6. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular
carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
7. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan
Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49:1109-13.
8. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, et al. Surveillance imaging and alpha fetoprotein for early detection of
hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
9. Jeong WK. Surveillance of hepatocellular carcinoma: is only ultrasound enough? Clin Mol Hepatol 2017;23:222-3.
10. Lee CI, Chen LE, Elmore JG. Risk-based breast cancer screening: implications of breast density. Med Clin North Am 2017;101:725-41.
11. Berg WA, Blume JD, Cormack JB, Mendelson EB. Operator dependence of physician-performed whole-breast US: lesion detection and
characterization. Radiology 2006;241:355-65.
12. Madjar H, Rickard M, Jellins J, Otto R. IBUS guidelines for the ultrasonic examination of the breast. Eur J Ultrasound 1999;9:99-102.
13. Choi EJ, Lee EH, Kim YM, Chang YW, Lee JH, et al; on the behalf of the Alliance for Breast Cancer Screening in Korea (ABCS-K).
Interobserver agreement in breast ultrasound categorization in the Mammography and Ultrasonography Study for Breast Cancer
Screening Effectiveness (MUST-BE) trial: results of a preliminary study. Ultrasonography 2019;38:172-80.
14. Finberg HJ. Whither (wither?) the ultrasound specialist? J Ultrasound Med 2004;23:1543-7.
15. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma
surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77.
16. Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, et al. The high burden of alcoholic cirrhosis in privately insured persons in
the United States. Hepatology 2018;68:872-82.
17. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver
disease. World J Gastroenterol 2017;23:8263-76.
18. Schoenberger H, Fetzer D, Yokoo T, Marrero J, Singal AG. Correlates of ultrasound quality for HCC surveillance in patients with
cirrhosis. Gastroenterology 2020;158:S-91.
19. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, et al; Study Group of the Association of Italian Hemophilia Centers. A
6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood
2003;102:78-82.
20. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-
center cohort of patients with cirrhosis. Hepatology 2020; doi: 10.1002/hep.31159.
21. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, et al; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance
is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-7.
22. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al; Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire
(GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month
periodicities. Hepatology 2011;54:1987-97.
23. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol
2014;28:843-53.
24. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular
carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:870-7.
25. Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma
diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92.
26. Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, et al. Serum alpha-fetoprotein has high specificity for the early detection of
hepatocellular carcinoma after hepatitis C virus eradication in patients. Medicine (Baltimore) 2015;94:e901.
27. Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular
carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014;59:986-95.
28. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in
patients with cirrhosis. Hepatology 2017;65:1196-205.
29. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of
hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875-86.e6.
30. Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, et al. GALAD score detects early hepatocellular carcinoma in an international
cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4.
31. Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, et al. GALAD score for hepatocellular carcinoma detection in comparison with
liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531-8.
32. Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer
2019;18:114.
33. Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, et al. Detection of circulating tumor cells and their implications as a novel biomarker
for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology 2020; doi: 10.1002/hep.31165.
34. Chalasani NP, Ramasubramanian T, Bruinsma JJ, et al. Combined methlylated DNA and protein markers: An accurate blood-based test
for early stage detection of hepatocellular carcinoma, In American Association for the Study of Liver Diseases: Hepatology 2019; 70(S1):
72A-73A. Available from https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.30940 [Last accessed on 26 Aug 2020]
35. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed